KPAX002-1: Parkinson's Disease
Phase 2 ready. K-PAX Pharmaceuticals is seeking strategic investors or a co-development partner to assist us in fully completing our Phase 2 program and developing this breakthrough therapy into the first approved disease-modifying treatment for Parkinson's disease.
KPAX002-2: Alzheimer's Disease
Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment for impaired cognitive symptoms and apathy in Alzheimer's disease.
KPAX002-3: Amyotrophic Lateral Sclerosis (ALS)
Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment to slow the progression of Amyotrophic lateral sclerosis (ALS).